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Abstract 12 
Introduction: Drug supply problems are a known problem for pharmacies. Community and hospital 13 
pharmacies do everything they can to minimize impact on patients. This study aims to quantify the 14 
time spent by Flemish community pharmacies on drug supply problems. 15 
Methodology: During 18 weeks, employees of 25 community pharmacies filled in a template with the 16 
total time spent on drug supply problems. The template stated all the steps community pharmacies 17 
could undertake to manage drug supply problems. 18 
Results: Considering the median over the study period, the median time spent on drug supply 19 
problems was 25 min/week, with a minimum of 14 min/week and a maximum of 38 min/week. After 20 
calculating the median of each pharmacy, large differences were observed between pharmacies: about 21 
25% spent less than 15min/week and one fifth spent more than one hour per week. The steps on which 22 
community pharmacists spent most time are: (i) “check missing products from orders”, (ii) “contact 23 
wholesaler/manufacturers regarding potential drug shortages” and (iii) “communicating to patients”. 24 
These three steps account for about 50% of the total time spent on drug supply problems during the 25 
study period. 26 
Conclusion: Community pharmacies spend about half an hour per week on drug supply problems. 27 
Although 25 min per week does not seem that much, the time spent is not delineated and community 28 
pharmacists are constantly confronted with drug supply problems. 29 
1 Introduction 30 
Shortages of “human medicinal products”, later referred to as “drug” shortages, are no longer a new 31 
phenomenon (Baumer et al., 2004; Collins, 2013; De Weerdt et al., 2015a, 2017; European 32 
Association of Hospital Pharmacists, 2014; Fox et al., 2009; Pauwels et al., 2015; Pharmaceutical 33 
Group of the European Union, 2012). Different wordings are used to describe drug supply problems 34 
and additional different interpretations are perceived when discussing drug shortages (De Weerdt et 35 
al., 2015b). In this paper, the wording “drug supply problem” is used, a term that covers “drug supply 36 
disruptions” (i.e. when the supply of drugs does not meet the demand at the level of pharmacies and 37 
wholesalers) and “drug shortages” (i.e. when the supply of drugs does not meet the demand at 38 
consumer/patient level). 39 
Various causes of drug supply problems are described in literature (Barlas, 2013; Birgli®, 2013; De 40 
Weerdt et al., 2015c; European Medicines Agency, 2012; Gupta and Huang, 2013). Reputational 41 
damage, economic and health implications, increased workload are just a few examples on how drug 42 
supply problems affect different stakeholders in the supply chain of delivering the medicinal products 43 
to patients (APB, 2015; Daouphars, 2013; De Weerdt et al., 2017; Fox et al., 2009; Havrilesky et al., 44 
2012; IMS, 2011; Kaakeh et al., 2011; Metzger et al., 2012; Pharmaceutical Group of the European 45 
Union, 2012; Ventola, 2011). 46 
Fig 1 displays a simplified supply chain for human medicinal products in Belgium. Two types of 47 
wholesalers exist in Belgium: (i) general wholesalers and (ii) full-line wholesalers. Full-line 48 
wholesalers, in contrast to general wholesalers, have several obligations and rights. For example, full-49 
line wholesalers have the right to be supplied by the pharmaceutical companies. In turn, full-line 50 
wholesalers have the obligation to supply community pharmacies and to have a stock of two-third of 51 
all medicines available in Belgium (art 101) (Royal Decree concerning medicines for humand and 52 
veterinary use 14/12/2006). 53 
In Belgium (including Flanders) hospital pharmacies order the majority of their products directly from 54 
the manufacturer. Only a small number of products available in hospital pharmacies are ordered by 55 
full-line wholesalers. Community pharmacies, on the other hand, must order their products via 56 
wholesalers (art 3) (Belgian law on medicines 25/03/1964). Most frequently, a community pharmacy 57 
co-operates with one main full-line wholesaler and one back-up full-line wholesaler. In Belgium, a 58 
distinction is made between private and cooperative community pharmacies. Cooperative pharmacies 59 
engage for the purchase and distribution of medicinal products, resulting in mutual benefits for the 60 
pharmacies and patients. Due to the cooperation, pharmacies are able to exchange medicinal products 61 
between cooperative pharmacies within the same cooperation, which may be very beneficial for 62 
patients in case of short-term supply disruptions.  63 
According to previous papers, European community pharmacies spend a lot of time on managing drug 64 
supply problems to avoid patients’ impact (APB, 2015; Collins, 2013; De Boer et al., 2015). At 65 
European level, a survey concludes that community pharmacists spend between three and 15 hours a 66 
month on drug shortages (Medicine Shortages; Pharmaceutical Group of the European Union, 2012). 67 
Results of a previous questionnaire in the UK indicate a time spent of less than one hour to more than 68 
10 hours per week on drug supply problems (Collins, 2013). However, it remains unclear which step 69 
in the management process consumes most time. Therefore, the aim of this study is to quantify the 70 
time employees of Flemish community pharmacies spend on drug supply problems as well as to 71 
investigate in detail which steps are most time consuming. In this way, sustainable measures can be 72 
formulated to mitigate the problem of drug supply problems. 73 
2 Methods 74 
2.1 Study design 75 
Time spent by employees of Flemish community pharmacies was studied through a time-and-motion 76 
study, which is a non-interventional descriptive study (Zheng et al., 2011). Employees of the 77 
community pharmacies were asked to register all the time they spent on managing supply disruptions 78 
and drug shortages. Approval for this study was received from the Ethics Committee of the University 79 
Hospitals Leuven (S58539).  80 
In Belgium, community pharmacies are obliged to order their medicinal products from wholesalers 81 
(art. 3) (Belgian law on medicines 25/03/1964). Most community pharmacies have one main full-line 82 
wholesaler and one back up full-line wholesaler. If supply problems are experienced for a product, 83 
community pharmacies can contact other wholesalers to purchase the particular product or a substitute 84 
after consultation with the prescribing healthcare professional (art. 3 and art. 31) (Coordinated law 85 
concerning the practice of health care professions 10/05/2015; Federale overheidsdienst Justitie). Only 86 
when a supply disruption is the result of quota, community pharmacists can contact the manufacturer 87 
to purchase the product (art. 12) (Belgian law on medicines 25/03/1964). Pharmaceutical industry 88 
introduced quota to avoid parallel export. Quota are precisely calculated amounts based on the needs 89 
of the Belgian population, including a small margin to ensure continued supply and avoid surpluses to 90 
limit parallel export (De Weerdt et al., 2015c; Sapentis, 2013). 91 
Substitution of medicinal products is only allowed when the prescription states the international non-92 
proprietary name (INN) (art. 3 and art. 31) (Coordinated law concerning the practice of health care 93 
professions 10/05/2015; Federale overheidsdienst Justitie), or if the prescription concerns antibiotics 94 
or antimycotics for short term use. If the Belgian market has no therapeutic alternatives available, 95 
community pharmacists can order a substitute abroad. However, this is only possible for prescription 96 
medicinal products and if a statement of a healthcare professional is obtained (art. 14) (Royal decree 97 
regarding instructions for pharmacists 21/01/2009). Foreign therapeutic alternative medicinal products 98 
are not always considered for reimbursement. 99 
Through a convenience sample of pharmacists in the region of Leuven, three exploratory interviews 100 
were conducted to draft a template containing the different steps a community pharmacist and his 101 
personnel can undertake to manage drug supply disruptions. The interviews were based on a template 102 
from a previous study on time spent on drug supply problems in hospital pharmacies (De Weerdt et 103 
al., 2017). Six randomly selected community pharmacies validated the template. Minor improvements 104 
were implemented and consensus on this final draft was achieved. An English version of the template 105 
is presented in Table 1. The template is divided in three sections: (i) time spent on collecting 106 
information regarding the supply problem, (ii) time spent on obtaining a substitute, and (iii) time spent 107 
on settling the supply problem. 108 
Time spent for drug supply problems was measured. In this study, the wording “drug supply 109 
problems” covers “drug supply disruptions” and “drug shortages”. A “supply disruption” was defined 110 
as “when the supply of a standard product is interrupted”, meaning the time spent on quota was also 111 
included in this study. However, this “supply disruption” does not necessarily lead to a drug shortage 112 
in the community pharmacy. A “drug shortage” was defined as a “supply problem which leads to 113 
changing the standard therapy into a substituted therapy”. A substituted therapy could be a substitution 114 
between generic or biosimilar medicines, changing to an alternative therapy or postpone the therapy if 115 
no substitute was available. 116 
Blank templates for daily reporting during the study period were assembled in a map. The template 117 
needed to be filled in daily with the total time spent on supply problems, hence not specific per supply 118 
problem.  119 
2.2 Sample size calculation 120 
To obtain a representative sample size, the Association of Belgian Pharmacists (ABP) provided the 121 
numbers of the distribution of private community pharmacies in Flanders. The sample size was 122 
calculated considering: (i) the ratio private and cooperative pharmacies in Belgium; (ii) distribution of 123 
private community pharmacies in Flanders; (iii) a response rate of 20%; and (iv) the desired number of 124 
35 participating community pharmacies (30 private community pharmacies and five cooperative). 125 
Based on these figures, the authors asked ABP to provide a list of 150 randomly selected private 126 
community pharmacies. At the beginning of November 2015, an invitation was sent to the 150 private 127 
community pharmacies with the request to participate in this study. Due to a low response rate, 128 
pharmacists who did not respond within one week were contacted in order to reach the desired number 129 
of 30 participating private community pharmacies. 130 
Cooperative community pharmacies were gathered through Ophaco (association of cooperative 131 
pharmacies in Belgium). The invitation letter was posted on the intranet website of Ophaco. However, 132 
since there was no response to the intranet message, cooperative pharmacists were randomly selected 133 
and contacted by telephone to ask whether they would like to participate in the study. Eventually five 134 
cooperative community pharmacies consented to participate in the study.  135 
2.3 Data collection 136 
The study started on November 30th, 2015 and ended April 3rd, 2016. Participating pharmacists were 137 
contacted for a kick-off meeting before the start of the study for the provision of further information 138 
about the study and to deliver the map, containing the templates for all days during the study period as 139 
well as templates for one week before the study period. This extra week was added in order to 140 
familiarize the employees of the pharmacies with the reporting system; if they encountered difficulties, 141 
these could be solved before the study period.  142 
Completed templates were collected twice. In February 2016, templates from November 2015 until 143 
January 2016 were collected and the remaining templates were collected after the study ended, in 144 
April 2016. In March 2016, additional information which might be useful for the analysis of the results 145 
was gathered through a questionnaire. This additional information included questions on the location 146 
of the pharmacy, the number of patients visiting the pharmacy per day, the number of prescriptions 147 
dispensed per day, the stock management and the number of employees. The questionnaires were 148 
collected during the last visit. Community pharmacies contributed voluntarily and were not 149 
remunerated. 150 
2.4 Data analysis 151 
The time spent per week on each action to manage drug supply problems was collected in a database 152 
(Microsoft Excel 2013). Primary, descriptive analysis was performed due to a relatively small sample 153 
size. Medians and interquartile ranges (IQR) were used to express the variables, as the variables were 154 
not normally distributed. To control for potential correlation factors, the Pearson correlation was 155 
calculated. 156 
Some of the steps as stated in the template (see Table 1) were grouped under a common denominator. 157 
Under “gathering information” the following steps were considered: (i) check missing products from 158 
order; (ii) contact wholesaler or manufacturer regarding possible drug shortage; and (iii) collecting 159 
information about drug shortages. Under “search alternative treatment” the following steps were 160 
considered: (i) contact and consult with prescribing medical doctor; (ii) check if there is a generic or 161 
biosimilar available in the pharmacy; and (iii) check if there is an alternative treatment available in the 162 
pharmacy. “Ordering alternative treatment” contains: (i) contact wholesaler or manufacturer to place 163 
order; (ii) contact other pharmacies; and (iii) contact international pharmacy to order drugs from 164 
abroad. “Communication with patients” and “communication with other colleagues” were combined 165 
as “communication towards patients and colleagues”.  166 
Community pharmacies were excluded if they admitted or self-reported not to fill in the templates 167 
correctly. Preliminary results were shared with the participating community pharmacies via email and 168 
employees of the pharmacy were asked to validate the observed results and trends through a 169 
questionnaire. 170 
After a preliminary analysis of the data on the time spent on drug supply problems, community 171 
pharmacists were asked to validate the observed results and trends through email.  172 
3 Results 173 
A total of 35 community pharmacies started the study (about 1,33% of the Flemish community 174 
pharmacies), including 30 private community pharmacies and 5 cooperative community pharmacies. 175 
Eventually, 25 (i.e. 23 private and two cooperative community pharmacies) were retained for further 176 
analysis, which represents about 0.95% of the Flemish community pharmacies. Six community 177 
pharmacies dropped out and four community pharmacies were excluded based upon the exclusion 178 
criteria.  179 
The starting sample (N = 35) and the final 25 pharmacies are representative to the Flemish situation in 180 
terms of the geographical distribution. Concerning the type of pharmacies, an underrepresentation is 181 
detected for cooperative community pharmacies. In seven of the 25 community pharmacies included, 182 
only one pharmacist is employed. In 11 community pharmacies, the number of full time equivalent 183 
(FTE) pharmacists employed range from 1,25 to two. Six pharmacies employ three FTE pharmacists 184 
and only one participating community pharmacy employ five FTE pharmacists. 185 
Fig 2 represents the median time spent by the 25 community pharmacies, together with its IQR. The 186 
median time spent by the personnel of a community pharmacy on drug supply problems is 25 minutes 187 
per week, with a minimum of 14 minutes and a maximum of 38 minutes per week. The majority of the 188 
participating community pharmacists confirms our result, about six pharmacists argue that 25 min per 189 
week is too low. The minimum is observed in the week of Christmas (21/12/2015) and community 190 
pharmacists attributed this minimum to more closing days during this period. The maximum of 38 191 
minutes is observed in the second week of February. According to the participants, this can be 192 
explained due to an increase of ill persons or by certain drug shortages which required an increased 193 
time investment. This increased time investment is detected, among others, in an increase of 194 
communication with patients, informing them about the drug supply problem. 195 
In Fig 2 several outliers are observed. These outliers represent great differences among the community 196 
pharmacies. As displayed in Fig 3, enormous differences in the reported times are observed among the 197 
25 community pharmacies. The number of community pharmacies who spend on average less than 15 198 
min per week practically equals the number of community pharmacies who spend more than 60 199 
minutes per week on drug supply problems. About one third of the community pharmacies spend on 200 
average between 15 and 30 minutes per week on drug supply problems.  201 
Several aspects of a community pharmacy are considered as potential confounding factors, e.g. the 202 
number of patients helped per day, the number of prescriptions dispensed per day, the location of the 203 
community pharmacy and the stock management. However, no correlation is found between the total 204 
time spent by the community pharmacies and any of these factors (p > 0.5). 205 
The most time consuming step is gathering information on drug supply problems, which corresponds 206 
to almost half of the total time spent by community pharmacists (Fig 4). This step includes checking 207 
the orders for missing products, contacting wholesalers and manufacturers and collecting more 208 
information on drug shortages via the website of the Federal Agency of Medicines and Health 209 
Products (FAMHP). The second most time consuming step is the communication towards patients and 210 
colleagues. Patients do not always understand why their product is in shortage and thus why they need 211 
to switch to a substitute. Ordering this substitute at another wholesaler or in case of quota at the 212 
manufacturer was the third most time consuming step.  213 
Most of the time spent on managing drug supply problems is executed by the pharmacist himself 214 
(95%). The remaining five percent of the total time spent is accomplished by the pharmacy technician. 215 
It should be noticed that only 11 of the 25 community pharmacies have a pharmacy technician 216 
employed. Pharmacy technicians spend most of their time on contacting the wholesaler or 217 
manufacturer to receive more information on supply disruptions. Communication towards patients 218 
regarding the drug supply problems is the second most time consuming step for pharmacy technicians. 219 
4 Discussion 220 
Flemish community pharmacies spend about 25 minutes on drug supply problems, with a minimum of 221 
14 and a maximum of 38 minutes per week. The most time consuming step is searching for 222 
information on drug supply problems, which corresponds with almost half of the total time spent on 223 
managing drug supply problems. 224 
The median time spent on drug supply problems by community pharmacies is much lower than 225 
previously reported (Collins, 2013; Pharmaceutical Group of the European Union, 2012). Previous 226 
research reveals a range on the time spent by UK community pharmacists going from less than one 227 
hour a week to more than 10 hours per week on managing drug shortages (Collins, 2013). However, of 228 
the 371 respondents, only 10% spend less than one hour on drug shortages. Diverse explanations can 229 
clarify the observed difference with our result. First, differences in the applied research methodologies 230 
and semantics can result in differences in the time spent on drug shortages. A survey is often more 231 
subjective and therefore the result is probably an overestimation, while our study tries to be more 232 
objective. Second, national differences in the supply chain of community pharmacies might influence 233 
the time spent on drug supply problems. 234 
In the UK, there are two main supply chains. The first one is similar to the Belgian supply chain 235 
(pharmaceutical industry to wholesalers and wholesalers to pharmacies). The second possibility to 236 
supply medicines in the UK is by pharmaceutical industry selling directly to pharmacies (DTP) and 237 
paying distributors or wholesalers a fixed fee for delivery (The Association of the British 238 
Pharmaceutical Industry). Since the introduction of DTP-model, pharmacists spend apparently a lot 239 
more time on sourcing drugs, especially in comparison with the other “standard” supply chain 240 
(Kermani, 2010; The Pharmaceutical Journal, 2010). An important strength of the Belgian “standard” 241 
supply chain is that full-line wholesalers have medicinal products available of different pharmaceutical 242 
manufacturers. The DTP-model complicates the search towards generic or alternative medicines, 243 
which might result in an increased amount of time spent by community pharmacies in case of drug 244 
supply problems. However, more in-depth research is necessary to investigate the influence of the 245 
supply chain on the time spent by pharmacists on drug supply problems. 246 
The time community pharmacists spend on drug supply problems (± 25 min/week) also largely differs 247 
from the time spent by hospital pharmacists (± two hours/week) (De Weerdt et al., 2017). There are 248 
two important factors which can explain this difference: (i) the supply chain of pharmacies (see Fig 1) 249 
and (ii) the amount of products ordered. In Belgium, most hospital pharmacies order their products 250 
directly from the manufacturer and are mostly bound to tender-contracts. The size of the order in 251 
combination with limitations due to the contract complicates ordering the product with other 252 
manufacturers for hospital pharmacies. Community pharmacies, on the other hand, order their 253 
products from wholesalers. Smaller orders and the possibility of easily switching between full-line 254 
wholesalers for ordering generic or alternative medicines can clarify the observed difference between 255 
the time spent by hospital pharmacies and community pharmacies.  256 
About 90% of the total time spent on drug supply problems is spent by the community pharmacist 257 
himself. Taken into account that seven community pharmacies employ only one pharmacist, a median 258 
time spent of 25 minutes per week on drug shortages, can be experienced as a real problem for such 259 
pharmacies. Especially since the time spent on drug supply problems is not delineated, but rather a 260 
constant reminder of the problem.  261 
The study design has several advantages. By using self-reporting methodology, a relatively high 262 
number of community pharmacies could participate in the study (Emmerton and Jefferson, 1996; 263 
Rutter et al., 1998). Secondly, our results are based on the time spent by 25 private and cooperative 264 
community pharmacies. Thirdly, since drug supply problems vary over time, the widespread study 265 
period of 18 weeks is another advantage. However, on the other hand, this study period does not allow 266 
observing yearly fluctuations. A fourth bonus of this study consists of the profound way the issue of 267 
drug supply problems has been studied, which resulted in suggesting targeted measures (see further) to 268 
mitigate the problem. 269 
4.1 Study limitations 270 
Despite its advantages, this study has also its limitations. Six community pharmacies dropped out of 271 
the study because it was too time consuming, four other community pharmacies were excluded based 272 
on the exclusion criteria. There is a risk that also other community pharmacies experienced similar 273 
problems, but did not admit resulting in an underestimation of the total time spent on drug supply 274 
problems. 275 
Participants might have experienced their contribution as troublesome and time-consuming, leading to 276 
a risk of underreporting, especially when participants are burdened with work (Emmerton and 277 
Jefferson, 1996; Rutter et al., 1998). When validating our results, some participating pharmacists 278 
admitted they sometimes forgot to fill in the templates correctly and therefore the median time spent 279 
on drug supply problems is an underestimation. 280 
Different interpretation of the wording used in the template should be considered as a third limitation 281 
of the study. This can result in inaccurate reporting of the time spent between the different steps. 282 
However, the total time spent on drug supply problems by community pharmacists will remain the 283 
same. 284 
Our study suffers from a limited sample size of 25 community pharmacies. Since the templates were 285 
filled in manually and subsequently transferred manually to an Excel database, the sample size was 286 
restricted to guarantee the feasibility of the study. Additionally, the response rate was very low, as 287 
explained above, which resulted in originally 35 participating community pharmacies from which 10 288 
dropped out or were excluded. 289 
Although our sample is representative of the population of pharmacies in Belgium, no statistical 290 
formulae were applied to calculate the sample size or to test hypotheses given that there were no prior 291 
data about the time spent on drug supply problems in community pharmacies in Flanders. The data of 292 
our exploratory study may be informative for sample size calculations in future studies 293 
4.2 Potential solutions 294 
According to our results, gathering information is the most time consuming step and includes the 295 
following steps: (i) checking missing products from order; (ii) contacting wholesaler(s) or 296 
manufacturer regarding drug supply problem, and (iii) communication towards patients. Almost half 297 
of the total time spent on drug supply problems is spent on finding reliable information about the drug 298 
supply problem. By improving the communication between different stakeholders, together with the 299 
provision of reliable information about drug supply problems, the total time spent on drug supply 300 
problems can be reduced. 301 
Market authorization holders (MAHs) are obliged to report drug shortages to the national competent 302 
authorities of the member states of the European Union (Directive 2001/83/EC, art. 23a) (The 303 
European Parliament and the Council of the European Union, 2011). To ensure up to date and reliable 304 
information of the current supply problems, reporting systems should be user friendly for all parties 305 
(MAHs, national competent authorities, etc.). When MAHs fail to report drug shortages, member 306 
states should consider introducing sanctions (e.g. financial penalty). In Belgium, a proposal to 307 
introduce such penalties when MAHs do not report appropriately is now discussed (Yoleen Van 308 
Camp, 2017).  309 
In Belgium , the FAMHP publishes daily a list of the reported drug shortages on their website 310 
(Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten, 2014), but this list contains 311 
only drug shortages for which the supply is interrupted for more than 14 days. Drugs subjected to 312 
quota are not recorded in this list, however, another website (www.farmacontigentering.be) publishes 313 
a list of drugs which experience supply problems due to quota (Koninklijke Apothekersvereniging van 314 
Antwerpen (KAVA), 2009). Currently, both lists are not user friendly and are therefore not often 315 
consulted by pharmacies. Integrating these lists into the software program of pharmacies would be a 316 
great help and could reduce the total time spent by community and hospital pharmacies. 317 
Substitution is not allowed by the Belgian legislation, unless for International Nonproprietary Names 318 
(INN) prescriptions. Exceptions are made for prescriptions of antibiotics or antimycotics in an acute 319 
treatment, and these prescriptions are always considered as INN prescriptions (Federale 320 
overheidsdienst Justitie). The legislation on substitution implies that patients with a prescription of a 321 
drug experiencing supply problems are informed at the community pharmacy about the shortage. The 322 
prescribing physician needs to be contacted by the pharmacist in order to change the prescription, or to 323 
be revisited by the patient. Promoting INN prescriptions or allowing substitution in case of shortages 324 
are potential solutions to reduce the burden experienced by community pharmacists, prescribing 325 
physicians and patients. 326 
5 Conclusion 327 
This study provided exploratory results on the time spent by Flemish community pharmacists on drug 328 
supply problems as well as on the most time-consuming tasks within pharmacies. The sample of 329 
community pharmacies is relatively small, but representative for the Flemish situation and shows a 330 
large variation in the time spent. Though a median of 25 minutes per week seems not that much, the 331 
time spent on drug supply problems is not delineated and community pharmacists are constantly 332 
reminded of the problem. Further research in a larger sample of community pharmacies is needed to 333 
validate the results of this study. However, improving the provision of information about drug supply 334 
problems can reduce the total time spent by pharmacists. Similar results and recommendations were 335 
found for Belgian hospital pharmacies (De Weerdt et al., 2017). 336 
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Table 1: Template to report time spent on drug supply problems 462 






Collecting information about drug shortages 
  
Check missing products from order 
  
Contact wholesaler or manufacturer 
regarding possible drug supply problem   
Check stock to see if a drug shortage can 
cause a problem   
Check if there is a generic or biosimilar 
available in the pharmacy   
Check if there is an alternative treatment 
available in the pharmacy   
Contact and consult with prescribing medical 
doctor   
Pharmaceutical compounding at pharmacy 
  
Contact wholesaler or manufacturer to place 
order   
Contact other pharmacies 
  
Contact international pharmacy to order 
drugs from abroad   
Set consumer price for drugs from abroad 
  
Communication with other colleagues 
  
Communication with patients 
  





Fig 1: Supply chain of manufacturing and delivering human medicinal products 464 
API = Active Pharmaceutical Ingredient 465 
 = only a small part of the total products ordered by hospital pharmacies are ordered via 466 
wholesalers 467 
Fig 2: Median (IQR) time spent (in min) per week on supply problems by community 468 
pharmacies in Flanders (N = 25) 469 
° = outlier [1.5 IQR – 3 IQR] 470 
* = extreme (> 3 IQR) 471 
Fig 3: Distribution of community pharmacies (N = 25) based on the average time spent 472 
on drug supply problems in minutes per week 473 
Fig 4: Time spent (% of total time spent) on steps to manage drug supply problems by 474 
Flemish community pharmacies 475 
 476 
